Login to Your Account



bluebird bio Brings in $30M to Advance Gene Therapies

By Catherine Schaffer


Wednesday, April 20, 2011
A little over a year after its $35 million Series B financing, bluebird bio has returned for another $30 million, laying down a three-year cash runway for advancement of its gene therapy products for rare diseases. CEO Nick Leschly calls the financing, which brings in new investor ARCH Venture Partners, "opportunistic." Existing investors Third Rock Ventures, TVM Capital, Forbion Capital Partners and Easton Capital Investment Group also participated.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription